loading
Celldex Therapeutics Inc stock is traded at $22.55, with a volume of 166.85K. It is down -0.67% in the last 24 hours and down -5.18% over the past month. Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
See More
Previous Close:
$22.70
Open:
$22.71
24h Volume:
166.85K
Relative Volume:
0.19
Market Cap:
$1.51B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-8.7403
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
+2.91%
1M Performance:
-5.18%
6M Performance:
-34.03%
1Y Performance:
-41.05%
1-Day Range:
Value
$22.51
$23.20
1-Week Range:
Value
$20.91
$23.69
52-Week Range:
Value
$20.91
$53.18

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Name
Celldex Therapeutics Inc
Name
Phone
908-200-7500
Name
Address
53 FRONTAGE ROAD, HAMPTON
Name
Employee
160
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
CLDX's Discussions on Twitter

Compare CLDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CLDX
Celldex Therapeutics Inc
22.55 1.51B 9.98M -154.08M -159.66M -2.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.06 117.87B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
678.97 73.64B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
643.04 38.85B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
249.82 33.20B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
121.07 28.73B 3.30B -501.07M 1.03B -2.1146

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-13-25 Initiated UBS Buy
Oct-07-24 Initiated Citigroup Buy
Sep-30-24 Initiated Goldman Neutral
Sep-27-24 Downgrade Wolfe Research Outperform → Peer Perform
Jun-18-24 Initiated Stifel Buy
Jun-11-24 Initiated Wolfe Research Outperform
Dec-20-23 Initiated TD Cowen Outperform
Nov-10-23 Upgrade Wells Fargo Underweight → Equal Weight
Aug-22-23 Initiated Wells Fargo Underweight
Sep-17-21 Initiated Jefferies Buy
Sep-10-21 Initiated SVB Leerink Outperform
Jul-22-21 Initiated Guggenheim Buy
Feb-21-20 Initiated Cantor Fitzgerald Overweight
Aug-01-17 Resumed H.C. Wainwright Buy
Nov-07-16 Initiated Aegis Capital Buy
Mar-08-16 Downgrade Jefferies Buy → Hold
Mar-07-16 Downgrade Guggenheim Buy → Neutral
Mar-07-16 Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16 Downgrade Wedbush Outperform → Neutral
Mar-01-16 Initiated H.C. Wainwright Buy
Aug-11-15 Reiterated Brean Capital Buy
Aug-11-15 Reiterated Oppenheimer Outperform
Aug-11-15 Reiterated ROTH Capital Buy
Jun-02-15 Reiterated WBB Securities Strong Buy
Nov-17-14 Reiterated ROTH Capital Buy
Mar-04-14 Reiterated Oppenheimer Outperform
Jul-08-13 Reiterated Cantor Fitzgerald Buy
Mar-08-13 Reiterated Cantor Fitzgerald Buy
Feb-26-13 Reiterated Oppenheimer Outperform
Jan-10-13 Reiterated Cantor Fitzgerald Buy
Oct-02-12 Reiterated Oppenheimer Outperform
Sep-14-12 Reiterated Cantor Fitzgerald Buy
View All

Celldex Therapeutics Inc Stock (CLDX) Latest News

pulisher
Feb 17, 2025

TSP Capital Management Group LLC Lowers Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Celldex Therapeutics (CLDX) Expected to Announce Quarterly Earnings on Monday - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from Analysts at UBS Group - Defense World

Feb 16, 2025
pulisher
Feb 16, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

Brokers Issue Forecasts for CLDX Q1 Earnings - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Sovran Advisors LLC Acquires New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

UBS Group Initiates Coverage on Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

UBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Celldex Therapeutics (NASDAQ:CLDX) Sets New 1-Year LowWhat's Next? - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Celldex stock touches 52-week low at $20.99 amid market challenges - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

CLDXU.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH - br.ADVFN.com

Feb 12, 2025
pulisher
Feb 11, 2025

FY2025 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Celldex Therapeutics: Will They Get It Right After A Decade Of Failures? - Seeking Alpha

Feb 10, 2025
pulisher
Feb 10, 2025

CLDX’s latest rating updates from top analysts. - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

What is Leerink Partnrs' Estimate for CLDX FY2028 Earnings? - MarketBeat

Feb 10, 2025
pulisher
Feb 06, 2025

It is Poised to be a Bull Market for Celldex Therapeutics Inc (CLDX) - SETE News

Feb 06, 2025
pulisher
Feb 05, 2025

Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR

Feb 05, 2025
pulisher
Feb 05, 2025

Celldex Therapeutics Inc (CLDX)’s stock performance: a year in review - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

Investing in Celldex Therapeutics Inc (CLDX): What You Must Know - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

Checking in on Checkpoint Therapeutics Inc (CKPT) after recent insiders movement - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

Stephens initates Catalyst Pharmaceuticals Inc (CPRX) stock to an Overweight - Knox Daily

Feb 04, 2025
pulisher
Feb 01, 2025

Celldex Therapeutics (NASDAQ:CLDX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by SG Americas Securities LLC - Defense World

Jan 31, 2025
pulisher
Jan 31, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock outlook - Investing.com India

Jan 31, 2025
pulisher
Jan 30, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Australia

Jan 30, 2025
pulisher
Jan 29, 2025

Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews - Benzinga

Jan 29, 2025
pulisher
Jan 29, 2025

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Jan 29, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Forecasts CLDX FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Predicts CLDX FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 22, 2025
pulisher
Jan 20, 2025

Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat

Jan 20, 2025
pulisher
Jan 16, 2025

Analysts Provide Insight Into Celldex Therapeutics Inc’s (CLDX) Potential. - Stocks Register

Jan 16, 2025
pulisher
Jan 15, 2025

B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR

Jan 15, 2025
pulisher
Jan 14, 2025

Celldex stock hits 52-week low at $22.89 amid market challenges By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Celldex stock hits 52-week low at $22.89 amid market challenges - Investing.com India

Jan 14, 2025
pulisher
Jan 13, 2025

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowHere's What Happened - MarketBeat

Jan 13, 2025
pulisher
Jan 08, 2025

Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights

Jan 08, 2025

Celldex Therapeutics Inc Stock (CLDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Celldex Therapeutics Inc Stock (CLDX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Martin Samuel Bates
SVP AND CFO
Jun 14 '24
Option Exercise
10.16
20,169
204,990
45,297
Martin Samuel Bates
SVP AND CFO
Jun 14 '24
Sale
35.42
17,172
608,315
28,125
Crowley Elizabeth
SR. VP & CPDO
Jun 14 '24
Option Exercise
10.38
30,000
311,400
39,074
Crowley Elizabeth
SR. VP & CPDO
Jun 14 '24
Sale
34.87
30,000
1,045,962
9,074
Young Diane C.
SVP, CHIEF MEDICAL OFFICER
Jun 11 '24
Option Exercise
2.71
15,000
40,650
17,115
Crowley Elizabeth
SR. VP & CPDO
Jun 07 '24
Option Exercise
9.70
15,000
145,474
24,074
Crowley Elizabeth
SR. VP & CPDO
Jun 07 '24
Sale
35.06
15,000
525,873
9,074
Young Diane C.
SVP, CHIEF MEDICAL OFFICER
Jun 07 '24
Sale
35.26
45,000
1,586,844
2,115
Jimenez Freddy A.
SVP & GENERAL COUNSEL
Jun 05 '24
Option Exercise
10.38
9,540
99,025
35,464
Heath-Chiozzi Margo
SVP OF REGULATORY AFFAIRS
Jun 03 '24
Option Exercise
10.25
64,658
662,575
71,752
$32.60
price up icon 0.85%
$81.11
price up icon 2.37%
$20.80
price down icon 2.55%
$373.76
price up icon 0.77%
biotechnology ONC
$237.16
price up icon 2.69%
$120.98
price up icon 0.98%
Cap:     |  Volume (24h):